338 related articles for article (PubMed ID: 34251506)
1. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Arabi YM; Gordon AC; Derde LPG; Nichol AD; Murthy S; Beidh FA; Annane D; Swaidan LA; Beane A; Beasley R; Berry LR; Bhimani Z; Bonten MJM; Bradbury CA; Brunkhorst FM; Buxton M; Buzgau A; Cheng A; De Jong M; Detry MA; Duffy EJ; Estcourt LJ; Fitzgerald M; Fowler R; Girard TD; Goligher EC; Goossens H; Haniffa R; Higgins AM; Hills TE; Horvat CM; Huang DT; King AJ; Lamontagne F; Lawler PR; Lewis R; Linstrum K; Litton E; Lorenzi E; Malakouti S; McAuley DF; McGlothlin A; Mcguinness S; McVerry BJ; Montgomery SK; Morpeth SC; Mouncey PR; Orr K; Parke R; Parker JC; Patanwala AE; Rowan KM; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Tong SYC; Turgeon AF; Turner AM; Van de Veerdonk FL; Zarychanski R; Green C; Berry S; Marshall JC; McArthur C; Angus DC; Webb SA;
Intensive Care Med; 2021 Aug; 47(8):867-886. PubMed ID: 34251506
[TBL] [Abstract][Full Text] [Related]
2. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
; Higgins AM; Berry LR; Lorenzi E; Murthy S; McQuilten Z; Mouncey PR; Al-Beidh F; Annane D; Arabi YM; Beane A; van Bentum-Puijk W; Bhimani Z; Bonten MJM; Bradbury CA; Brunkhorst FM; Burrell A; Buzgau A; Buxton M; Charles WN; Cove M; Detry MA; Estcourt LJ; Fagbodun EO; Fitzgerald M; Girard TD; Goligher EC; Goossens H; Haniffa R; Hills T; Horvat CM; Huang DT; Ichihara N; Lamontagne F; Marshall JC; McAuley DF; McGlothlin A; McGuinness SP; McVerry BJ; Neal MD; Nichol AD; Parke RL; Parker JC; Parry-Billings K; Peters SEC; Reyes LF; Rowan KM; Saito H; Santos MS; Saunders CT; Serpa-Neto A; Seymour CW; Shankar-Hari M; Stronach LM; Turgeon AF; Turner AM; van de Veerdonk FL; Zarychanski R; Green C; Lewis RJ; Angus DC; McArthur CJ; Berry S; Derde LPG; Gordon AC; Webb SA; Lawler PR
JAMA; 2023 Jan; 329(1):39-51. PubMed ID: 36525245
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
4. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
[TBL] [Abstract][Full Text] [Related]
5. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
Lecronier M; Beurton A; Burrel S; Haudebourg L; Deleris R; Le Marec J; Virolle S; Nemlaghi S; Bureau C; Mora P; De Sarcus M; Clovet O; Duceau B; Grisot PH; Pari MH; Arzoine J; Clarac U; Boutolleau D; Raux M; Delemazure J; Faure M; Decavele M; Morawiec E; Mayaux J; Demoule A; Dres M
Crit Care; 2020 Jul; 24(1):418. PubMed ID: 32653015
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
[TBL] [Abstract][Full Text] [Related]
8. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
[TBL] [Abstract][Full Text] [Related]
9. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
[TBL] [Abstract][Full Text] [Related]
10. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
[TBL] [Abstract][Full Text] [Related]
11. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
; Bradbury CA; Lawler PR; Stanworth SJ; McVerry BJ; McQuilten Z; Higgins AM; Mouncey PR; Al-Beidh F; Rowan KM; Berry LR; Lorenzi E; Zarychanski R; Arabi YM; Annane D; Beane A; van Bentum-Puijk W; Bhimani Z; Bihari S; Bonten MJM; Brunkhorst FM; Buzgau A; Buxton M; Carrier M; Cheng AC; Cove M; Detry MA; Estcourt LJ; Fitzgerald M; Girard TD; Goligher EC; Goossens H; Haniffa R; Hills T; Huang DT; Horvat CM; Hunt BJ; Ichihara N; Lamontagne F; Leavis HL; Linstrum KM; Litton E; Marshall JC; McAuley DF; McGlothlin A; McGuinness SP; Middeldorp S; Montgomery SK; Morpeth SC; Murthy S; Neal MD; Nichol AD; Parke RL; Parker JC; Reyes LF; Saito H; Santos MS; Saunders CT; Serpa-Neto A; Seymour CW; Shankar-Hari M; Singh V; Tolppa T; Turgeon AF; Turner AM; van de Veerdonk FL; Green C; Lewis RJ; Angus DC; McArthur CJ; Berry S; Derde LPG; Webb SA; Gordon AC
JAMA; 2022 Apr; 327(13):1247-1259. PubMed ID: 35315874
[TBL] [Abstract][Full Text] [Related]
12. Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.
Andy Ko TY; Chen LS; Pang IX; Ling HS; Wong TC; Sia Tonnii LL; Koh KT
Med J Malaysia; 2021 Mar; 76(2):125-130. PubMed ID: 33742617
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.
Gaibani P; Tonetti T; Bartoletti M; Re MC; Viale P; Ranieri VM
J Glob Antimicrob Resist; 2021 Mar; 24():124-126. PubMed ID: 33385588
[No Abstract] [Full Text] [Related]
14. An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.
Ader F;
Clin Microbiol Infect; 2022 Sep; 28(9):1293-1296. PubMed ID: 35533972
[No Abstract] [Full Text] [Related]
15. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
[TBL] [Abstract][Full Text] [Related]
16. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
Giacomelli A; Pagani G; Ridolfo AL; Oreni L; Conti F; Pezzati L; Bradanini L; Casalini G; Bassoli C; Morena V; Passerini S; Rizzardini G; Cogliati C; Ceriani E; Colombo R; Rusconi S; Gervasoni C; Cattaneo D; Antinori S; Galli M
J Med Virol; 2021 Mar; 93(3):1421-1427. PubMed ID: 32776534
[TBL] [Abstract][Full Text] [Related]
17. Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
Schneider J; Jaenigen B; Wagner D; Rieg S; Hornuss D; Biever PM; Kern WV; Walz G
PLoS One; 2021; 16(5):e0249760. PubMed ID: 33974624
[TBL] [Abstract][Full Text] [Related]
18. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
[TBL] [Abstract][Full Text] [Related]
19. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.
Alavi Darazam I; Shokouhi S; Mardani M; Pourhoseingholi MA; Rabiei MM; Hatami F; Shabani M; Moradi O; Gharehbagh FJ; Irvani SSN; Amirdosara M; Hajiesmaeili M; Rezaei O; Khoshkar A; Lotfollahi L; Gachkar L; Dehbsneh HS; Khalili N; Soleymaninia A; Kusha AH; Shoushtari MT; Torabinavid P
Int Immunopharmacol; 2021 Oct; 99():107969. PubMed ID: 34273635
[TBL] [Abstract][Full Text] [Related]
20. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
